hVIVO (LON:HVO) Releases Quarterly Earnings Results

hVIVO (LON:HVO) released its earnings results on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Stock Performance

Shares of LON HVO traded down GBX 0.36 during trading on Tuesday, reaching GBX 6.04. 4,506,074 shares of the company traded hands, compared to its average volume of 2,552,195. The stock has a market cap of £41.55 million, a P/E ratio of -6.94 and a beta of 1.69. The firm’s fifty day simple moving average is GBX 6.83 and its 200 day simple moving average is GBX 7.42. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75. hVIVO has a 12-month low of GBX 4.30 and a 12-month high of GBX 11.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.